Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention
Issued Date
2022-12-01
Resource Type
eISSN
14203049
Scopus ID
2-s2.0-85143685990
Pubmed ID
36500236
Journal Title
Molecules
Volume
27
Issue
23
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules Vol.27 No.23 (2022)
Suggested Citation
Mungchan P., Glab-ampai K., Chruewkamlow N., Trakarnsanga K., Srisawat C., Nguyen K.T., Chaicumpa W., Punnakitikashem P. Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention. Molecules Vol.27 No.23 (2022). doi:10.3390/molecules27238144 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83505
Title
Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention
Author's Affiliation
Other Contributor(s)
Abstract
Percutaneous coronary intervention (PCI) is a common procedure for the management of coronary artery obstruction. However, it usually causes vascular wall injury leading to restenosis that limits the long-term success of the PCI endeavor. The ultimate objective of this study was to develop the targeting nanoparticles (NPs) that were destined for the injured subendothelium and attract endothelial progenitor cells (EPCs) to the damaged location for endothelium regeneration. Biodegradable poly(lactic-co-glycolic acid) (PLGA) NPs were conjugated with double targeting moieties, which are glycoprotein Ib alpha chain (GPIbα) and human single-chain antibody variable fragment (HuscFv) specific to the cluster of differentiation 34 (CD34). GPIb is a platelet receptor that interacts with the von Willebrand factor (vWF), highly deposited on the damaged subendothelial surface, while CD34 is a surface marker of EPCs. A candidate anti-CD34 HuscFv was successfully constructed using a phage display biopanning technique. The HuscFv could be purified and showed binding affinity to the CD34-positive cells. The GPIb-conjugated NPs (GPIb-NPs) could target vWF and prevent platelet adherence to vWF in vitro. Furthermore, the HuscFv-conjugated NPs (HuscFv-NPs) could capture CD34-positive cells. The bispecific NPs have high potential to locate at the damaged subendothelial surface and capture EPCs for accelerating the vessel repair.